Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals Inc (NQ: VRPX )

0.7400 -0.0331 (-4.28%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 271,537
Open 0.7673
Bid (Size) 0.7003 (10)
Ask (Size) 0.7450 (2)
Prev. Close 0.7731
Today's Range 0.6316 - 0.7689
52wk Range 0.2402 - 5.480
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gold Rises Over 1%; Arcos Dorados Shares Fall After Q1 Results
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga

Performance

YTD
+131.97%
+131.97%
1 Month
-77.58%
-77.58%
3 Month
+174.07%
+174.07%
6 Month
+19.16%
+19.16%
1 Year
-9.80%
-9.80%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Surges 150 Points; Retail Sales Flat For April
Via Benzinga
Dow Jumps 200 Points; US Inflation Rate Slows In April
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Castellum (CTM) Stock Down 16% Today?
Via InvestorPlace
Why Is Virpax Pharmaceuticals (VRPX) Stock Down 61% Today?
Via InvestorPlace
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Virpax Announces Pricing of $2.25 Million Public Offering
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
VRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q1 2024
Via InvestorPlace
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
VRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Virpax Pharmaceuticals Reports 2023 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.